Valuation : Valneva SE

Market Cap 566M 657M 534M 486M 909M 62.03B 916M 6.32B 2.45B 31.71B 2.47B 2.41B 104B P/E 2026 *
-6.86x
P/E 2027 * 10.8x
Enterprise Value 700M 812M 660M 601M 1.12B 76.67B 1.13B 7.81B 3.03B 39.2B 3.05B 2.98B 129B EV / Sales 2026 *
4.64x
EV / Sales 2027 * 2.22x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
1 day+6.45%
1 week+3.21%
Current month+10.30%
1 month+39.06%
3 months+19.15%
6 months-36.85%
Current year-19.66%
1 week 2.62
Extreme 2.62
2.99
1 month 2.15
Extreme 2.15
3.24
Current year 2.03
Extreme 2.033
5.15
1 year 2.03
Extreme 2.033
5.34
3 years 1.73
Extreme 1.726
7.17
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Date Insider Type Main position Quantity % Market Cap. Importance
27/01/26 Sell

Chief Technology Officer

11,800 0.0069%
26/01/26 Sell

Chief Financial Officer

11,800 0.0069%
19/01/26 Exercice

Chief Technology Officer

82,899 0.0482%
Change 5-day change 1-year change 3-year change Capi.($)
+6.45%+3.21%-20.39%-53.60% 617M
+0.97%-1.75%+2.17%+18.46% 49.74B
-0.30%-2.88%+429.29%+521.04% 44.98B
+2.13%+0.89%+43.59%+19.44% 42.52B
+0.87%-3.73%+8.96%+76.62% 40.78B
-0.90%-1.74%+15.20%+48.44% 32.89B
+2.71%+6.82% - - 17.09B
+1.68%-4.20%+25.28%+123.70% 16.28B
+1.70%-1.75%+12.00%+28.50% 14.4B
+3.34%-1.13%+80.94%+42.82% 13.48B
Average +1.87%-2.49%+66.34%+91.71% 27.28B
Weighted average by Cap. +1.03%-2.25%+93.09%+128.55%

Financials

2026 *2027 *
Net sales 151M 175M 142M 130M 242M 16.53B 244M 1.68B 654M 8.45B 657M 643M 27.77B 283M 328M 267M 243M 455M 31.03B 458M 3.16B 1.23B 15.86B 1.23B 1.21B 52.11B
Net income -81.11M -94.02M -76.41M -69.62M -130M -8.88B -131M -905M -351M -4.54B -353M -345M -14.92B 53.07M 61.52M 50M 45.55M 85.14M 5.81B 85.78M 592M 230M 2.97B 231M 226M 9.76B
Net Debt 134M 155M 126M 115M 215M 14.64B 216M 1.49B 579M 7.49B 582M 569M 24.59B 62.48M 72.42M 58.85M 53.62M 100M 6.84B 101M 697M 270M 3.5B 272M 266M 11.49B
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
620
Date Price Change Volume
02/09/26 2.987 +6.45% 1,431,033
01/09/26 €2.806 +3.62% 760,088
31/08/26 €2.708 -3.15% 5,284,639
28/08/26 €2.796 -0.67% 421,759
27/08/26 €2.815 -0.88% 577,691
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.806EUR
Average target price
6.193EUR
Spread / Average Target
+120.70%

Quarterly revenue - Rate of surprise